These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 17585375)
1. Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy. Cai JP; Cheng JW; Wei RL; Ma XY; Jiang F; Zhu H; Li Y Int Ophthalmol; 2008 Feb; 28(1):19-22. PubMed ID: 17585375 [TBL] [Abstract][Full Text] [Related]
2. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C Eur J Ophthalmol; 1998; 8(3):167-72. PubMed ID: 9793771 [TBL] [Abstract][Full Text] [Related]
3. [Intraocular pressure changes after Nd:YAG laser capsulotomy with preoperative use of timolol]. Yang W; Liu Y; Li S Yan Ke Xue Bao; 1991 Jun; 7(2):86-8. PubMed ID: 1669483 [TBL] [Abstract][Full Text] [Related]
4. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Unal M; Yücel I; Akar Y J Cataract Refract Surg; 2006 Sep; 32(9):1499-502. PubMed ID: 16931262 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy of topic ocular hipotensive agents after posterior capsulotomy]. Minello AA; Prata Junior JA; Mello PA Arq Bras Oftalmol; 2008; 71(5):706-10. PubMed ID: 19039468 [TBL] [Abstract][Full Text] [Related]
7. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. Yeom HY; Lee JH; Hong YJ; Seong GJ J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678 [TBL] [Abstract][Full Text] [Related]
8. Prevention of IOP-rise following Nd-YAG laser capsulotomy with topical timolol and indomethacin. Van der Feltz van der Sloot D; Stilma JS; Boen-Tan TN; Bezemer PD Doc Ophthalmol; 1988; 70(2-3):209-14. PubMed ID: 3234187 [TBL] [Abstract][Full Text] [Related]
9. Long-term elevation of intraocular pressure after neodymium: YAG laser posterior capsulotomy. Jahn CE; Emke M Ophthalmologica; 1996; 210(2):85-9. PubMed ID: 9148259 [TBL] [Abstract][Full Text] [Related]
10. Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy. Gartaganis SP; Mela EK; Katsimpris JM; Petropoulos JK; Karamanos NK; Koliopoulos JX Ophthalmic Surg Lasers; 1999; 30(8):647-52. PubMed ID: 10507567 [TBL] [Abstract][Full Text] [Related]
11. Prevention of IOP-rise following Nd-YAG laser capsulotomy with pre-operative timolol eye-drops and 1 tablet acetazolamide 250 mg systematically. Boen-Tan TN; Stilma JS Doc Ophthalmol; 1986 Dec; 64(1):59-67. PubMed ID: 3582103 [TBL] [Abstract][Full Text] [Related]
12. Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Öner V; Alakuş MF; Taş M; Türkyılmaz K; Işcan Y J Ocul Pharmacol Ther; 2012 Dec; 28(6):576-80. PubMed ID: 22809091 [TBL] [Abstract][Full Text] [Related]
13. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy. Ladas ID; Baltatzis S; Panagiotidis D; Zafirakis P; Kokolakis SN; Theodossiadis GP Arch Ophthalmol; 1997 Oct; 115(10):1241-4. PubMed ID: 9338667 [TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of acetazolamide to prevent intraocular pressure elevation following Nd-YAG laser posterior capsulotomy. Ladas ID; Pavlopoulos GP; Kokolakis SN; Theodossiadis GP Br J Ophthalmol; 1993 Mar; 77(3):136-8. PubMed ID: 8457502 [TBL] [Abstract][Full Text] [Related]
15. The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. Elmi Sadr N; Saber E; Paknazar F Clin Exp Optom; 2022 Nov; 105(8):813-816. PubMed ID: 34753412 [TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome. Levkovitch-Verbin H; Habot-Wilner Z; Burla N; Melamed S; Goldenfeld M; Bar-Sela SM; Sachs D Ophthalmology; 2008 Jan; 115(1):104-8. PubMed ID: 17561259 [TBL] [Abstract][Full Text] [Related]